720 A phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers

• Edith A Perez,
• Lu Xu,
• Antonio Giordano,
• Justin Kenkel,
• Shelley E Ackerman,
• Michael N Alonso,
• Sharon Wilks,
• Aparna R Parikh,
• Danlin Cai,
• Damon Demady

Affiliations

Edith A Perez

Mayo Clinic Jacksonville Jacksonville, Florida, USA

Lu Xu

2Ningbo University School of Medicine, Ningbo, China

Antonio Giordano

1Dana-Farber Cancer Institute, Boston, MA, USA

Justin Kenkel

Bolt Biotherapeutics

Shelley E Ackerman

1Bolt Biotherapeutics, Redwood City, CA, USA

Michael N Alonso

31Bolt Biotherapeutics, Redwood City, CA, USA

Sharon Wilks

1NEXT Oncology, San Antonio, TX, USA

Aparna R Parikh

2Mass General Cancer Center, Harvard Medical School Hospital, Charlestown, MA, USA

Danlin Cai

4Bolt Biotherapeutics Inc, Redwood City, CA, USA

Damon Demady

4Bolt Biotherapeutics Inc, Redwood City, CA, USA